Establishment of S180 Tumor Multidrug Resistance Mouse Model by Increasing PFC and Observation on Stability

doi:10.3969/j.issn.1674-5817.2015.05.005

Abstract

Abstract: Objective To establish aquired S180 multidrug resistance (MDR) mouse model and study on its stability. Methods To mimic the clinical PFC (cis-Dichlorodiamineplatinum+5-Fluorouracil+cyclophosphamide) scheme, gradually increase the dose in three phases to induce S180 ascites tumor mice and establish the aquired S180 MDR mouse model. The induced cells resistance factor to the chemotherapeutics drugs in different stages, the accumulation of adriamycin (ADR) and the functional activity of P-glycoprotein (P-gp) were detected by MTT assay and flow cytometry. And then through detecting the above indicators to monitor the resistance drug stability of induced cells in different stages. The mRNA expression of MDR-1 and multidrug resistance-associated protein 1 (MRP-1) of induced cells in different stages were detected by real time quantitative PCR (RT-qPCR). Results Compared with the parent cells, with induction time extending and dose increasing, the resistance factors in each stage of induced S180 cells to chemotherapeutics drugs were gradually increased, the accumulation of ADR was gradually reduced, and the functional activity of P-gp was strengthened. The mRNA expression of MDR-1 and MRP-1 of induced cells in different stages had a positive correlation to the induction time and dose. The stable resistance time of induced cells in the first, second and third phase are respectively for about 1 week, 2 weeks and 3 weeks. Conclusion To mimic the clinical PFC scheme, using the dose gradually increasing by phased can establish a high resistant strength, long stable time aquired S180MDR experimental model.

Key words: cis-Dichlorodiamineplatinum+5-Fluorouracil+cyclophosphamide (PFC), Multidrug resistance, S180 cell line, in vivo, P-gp, multidrug resistance-1(MDR-1mRNA), multidrug resistance-associated protein-1(MRP-1 mRNA)

CLC Number:

Q95-33

GU Yun-hao, CAO Chen-jie, HU Bi-yuan, WANG Jun, HAN Dong-dong, XU Ai-hua. Establishment of S180 Tumor Multidrug Resistance Mouse Model by Increasing PFC and Observation on Stability[J]. Laboratory Animal and Comparative Medicine, 2015, 35(5): 367-373.

References

[1] Huang F, Wu XN, Chen J, et al.Resveratrol reverses multidrug resistance in human breast cancer doxorubicin-resistant cells[J]. Exp Ther Med, 2014.7:1611-1616.
[2] Zhang QY, Wang JZ, He HB, et al.Trametenolic acid B reverses multidrug resistance in breast cancer cells through regulating the expression level of P-Glycoprotein[J]. Phytother Res,2014, 28:1037-1044.
[3] 刘晓冬, 常青, 赵秀芳, 等. 多西他赛诱导肺腺癌A549/DTX细胞株的建立及耐药机制分析[J]. 肿瘤防治研究, 2014, 41(6):519-522.
[4] Tian QE, Li HD, Yan M, et al.Effects of astragalus polysaccharides on P-glycoprotein efflux pump function and protein expression in H22 hepatoma cells in vitro[J]. BMC Complement Altern Med, 2012, 12:94.
[5] Zhou Y, Ling XL, Li SW, et al.Establishment of a human hepatoma multidrug resistant cell line in vitro[J]. World J Gastroenterol, 2010, 16(18):2291-2297.
[6] Li GY, Liu JZ, Zhang B, et al.Tegillarca granosa extract Haishengsu (HSS) suppresses expression of mdr1, BCR/ABL and sorcin in drug-resistant K562/ADR tumors in mice[J]. Adv Med Sci, 2013, 58(1):112-117.
[7] 黄永明, 苏海涛, 黄启明, 等. 人骨肉瘤耐药性KH-OS/ADR细胞SCID小鼠移植模型的建立及其生物学特征的研究[J]. 中国中医骨伤科杂志, 2013, 21(7):1-3.
[8] Zrieki A, Farinotti R, Buyse M.Cyclooxygenase-2 inhibitors prevent trinitrobenzene sulfonic acid-induced P-glycoprotein up-regulation in vitro and in vivo[J]. Eur J Pharmacol,2010, 636(1-3):189-197.
[9] Loetchutinat C, Saengkhae C, Marbeuf-Gueye C, et al.New insights into the P-glycoprotein-mediated effluxes of rhodamines[J]. Eur J Biochem, 2003, 270(3):476-485.
[10] Snow K, Judd W.Characteristion of adriamycin and amsacrine-resistant human leukaemic T cell lines[J]. Br J Cancer, 1991,63(1):17-28.
[11] 徐龙进, 王祖海, 孙付军, 等. 联合化疗诱导小鼠在体肿瘤多药耐药模型的建立[J]. 实验动物与比较医学, 2005, 25(4):215-217.
[12] 陈强, 李贵海, 孙付军, 等. 适合中药研究的小鼠S180肿瘤获得性多药耐药模型的建立及稳定性研究[J].中草药, 2006, 37(11):1691-1694.
[13] 尹格平, 顾清, 陈铭, 等. 腹水型S180细胞系获得性MDR表达鼠模型的建立[J]. 上海免疫学杂志, 2001, 21(5):282-285.
[14] Juranka PF, Zastawny RL, Ling V.P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins[J]. FASEB J, 1989, 3(14):2583-2592.
[15] Molinas A, Sicard G, Jakob I.Functional evidence of multidrug resistance transporters (MDR) in rodent olfactory epithelium[J]. PLoS One, 2012, 7(5):1-13.
[16] Hennessy M, Spiers JP.A primer on the mechanics of P-glycoprotein the multidrug transporter[J]. Pharmacol Res, 2007, 55(1):1-15.
[17] Villar VH, V gler O, BarcelóF, et al. Oleanolic and maslinic acid sensitize soft tissue sarcoma cells to doxorubicin by inhibiting the multidrug resistance protein MRP-1, but not P-glycoprotein[J]. J Nutr Biochem, 2014, 25:429-438.